[en] The discovery of biomarkers that are readily accessible through the circulating blood and are selectively overexpressed in pathological tissues has become a major research objective, particularly in the field of oncology. Indisputably, this group of molecules has a high potential
to serve as an innovative tool for effective imaging and targeted cancer therapy approaches. In this attractive therapeutic concept, specific cancer proteins are reached by intravenously administered ligands that are coupled to cytotoxic drugs. Such compounds are able to induce cancer destruction while sparing normal tissues. Owing to the performance of mass spectrometry technology, current high-throughput proteomic analysis allows for the identification of a high number of proteins that are differentially expressed in the cancerous tissues. However, such approaches provide no information regarding the effective accessibility of the biomarkers and, therefore, the possibility for these discovered proteins to be targeted. To bypass this major limitation, which clearly slows the discovery of such biomarkers, innovative methodological strategies have been developed to enrich the clinical specimens before the mass
spectrometry analysis. The focus is laid on the group of proteins that are necessarily located either at the exterior face of the plasma membrane or in the extracellular matrix. The present review addresses the current technologies meant for the discovery and analysis of accessible antigens from clinically relevant samples.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Turtoi, Andrei ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases
De Pauw, Edwin ; Université de Liège - ULiège > Département de chimie (sciences) > GIGA-R : Laboratoire de spectrométrie de masse (L.S.M.)
Castronovo, Vincenzo ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire
Language :
English
Title :
Innovative Proteomics for the Discovery of Systemically Accessible Cancer Biomarkers Suitable for Imaging and Targeted Therapies
Publication date :
January 2011
Journal title :
American Journal of Pathology
ISSN :
0002-9440
eISSN :
1525-2191
Publisher :
American Society for Investigative Pathology, Bethesda, United States - Maryland
Volume :
178
Issue :
1
Pages :
12-18
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
Supported by grants from the Research Concerted Action program (IDEA project), from the CEE [FP7 network: ADAMANT-Antibody derivatives as molecular agents for neoplastic targeting (HEALTH-F2-2007-201342)], from the National Fund for Scientific Research (NFSR, Belgium), from TELEVIE, from the Centre Anti-Cancéreux of the University of Liège, and is made in collaboration with the GIGA-Proteomics Platform at the University of Liège, Belgium.
Strebhardt K, Ullrich A: Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008, 8:473-480 (Pubitemid 351752547)
Kischel P, Waltregny D, Castronovo V: Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies. Expert Rev Proteomics 2007, 4:727-739 (Pubitemid 350261439)
Rybak JN, Trachsel E, Scheuermann J, Neri D: Ligand-based vascular targeting of disease. Chem Med Chem 2007, 2:22-40
Mantovani A: Role of inflammatory cells and mediators in tumor invasion and metastasis. Cancer Metastasis Rev 2010, 29:241
Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN: Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009, 50:974-981
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA: Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008, 35:1857-1867
Duong HK, Sekeres MA: Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging 2009, 4:197-205
Smith S, Sweetenham JW: Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma. Future Oncol 2007, 3:255-262
Kaspar M, Zardi L, Neri D: Fibronectin as target for tumor therapy. Int J Cancer 2006, 118:1331-1339
Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L: Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003, 102:4384-4392 (Pubitemid 37494099)
Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA: Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 2006, 47:1127-1235
Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Dürkop H, Menssen HD: Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113:2265-2274
Brack SS, Silacci M, Birchler M, Neri D: Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006, 12:3200-3208 (Pubitemid 43837370)
Silacci M, Brack SS, Späth N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D: Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 2006, 19:471-478
Berndt A, Anger K, Richter P, Borsi L, Brack S, Silacci M, Franz M, Wunderlich H, Gajda M, Zardi L, Neri D, Kosmehl H: Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. J Cancer Res Clin Oncol 2006, 132:537-546
Anderson NL, Anderson NG, Pearson TW, Borchers CH, Paulovich AG, Patterson SD, Gillette M, Aebersold R, Carr SA: A human proteome detection and quantitation project. Mol Cell Proteomics 2009, 8:883-886
Wang Y, Seneviratne J. Biomarker discovery in clinical proteomics: strategies for exposing low abundant proteins. Current Proteomics 2008, 5:104-114 (Pubitemid 351988581)
Righetti PG, Boschetti E, Lomas L, Citterio A: Protein Equalizer Technology: the quest for a "democratic proteome." Proteomics 20066:3980-3992
Waanders LF, Chwalek K, Monetti M, Kumar C, Lammert E, Mann M: Quantitative proteomic analysis of single pancreatic islets. Proc Natl Acad Sci U S A 2009, 106:18902-18907
Tan S, Tan HT, Chung MC: Membrane proteins and membrane proteomics. Proteomics 2008, 8:3924-3932
Rybak JN, Scheurer SB, Neri D, Elia G: Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics 2004, 4:2296-2299
Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, Elia G: In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2005, 2:291-298
Castronovo V, Waltregny D, Kischel P, Roesli C, Elia G, Rybak JN, Neri D: A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 2006, 5:2083-2091
Conrotto P, Roesli C, Rybak J, Kischel P, Waltregny D, Neri D, Castronovo V: Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer 2008, 123:2856-2864
Castronovo V, Kischel P, Guillonneau F, de Leval L, Deféchereux T, De Pauw E, Neri D, Waltregny D: Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. Proteomics 2007, 7:1188-1196
Roesli C, Mumprecht V, Neri D, Detmar M: Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping. FASEB J 2008, 22:1933-1944
Kischel P, Guillonneau F, Dumont B, Bellahcène A, Stresing V, Clézardin P, De Pauw EA, Castronovo V: Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia 2008, 10:1014-1020
Brooks SA: Strategies for analysis of the glycosylation of proteins: current status and future perspectives. Mol Biotechnol 2009, 43: 76-88
Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nature Biotechnol 2003, 21:660-666
Tian Y, Zhou Y, Elliott S, Aebersold R, Zhang H: Solid-phase extraction of N-linked glycopeptides. Nat Protoc 2007, 2:334-339
Whelan SA, Lu M, He J, Yan W, Saxton RE, Faull KF, Whitelegge JP, Chang HR: Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers. J Proteome Res 2009, 8:4151-4160
Arcinas A, Yen TY, Kebebew E, Macher BA: Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res 2009, 8:3958-3968
Cao J, Shen C, Wang H, Shen H, Chen Y, Nie A, Yan G, Lu H, Liu Y, Yang P: Identification of N-glycosylation sites on secreted proteins of human hepatocellular carcinoma cells with a complementary proteomics approach. J Proteome Res 2009, 8:662-672
Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, Wang L, Zou H: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res 2009, 8:651-661
Rajcevic U, Niclou SP, Jimenez CR: Proteomics strategies for target identification and biomarker discovery in cancer. Front Biosci 2009, 14:3292-3303
Ahmed FE: Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry. J Sep Sci 2009, 32:771-798
Patton WF: Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 771:3-31
Heeren RM, Smith DF, Stauber J, Kükrer-Kaletas B, MacAleese L: Imaging mass spectrometry: hype or hope? J Am Soc Mass Spectrom 2009, 20:1006-1014
Diamandis EP: Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004, 3:367-378
Knochenmuss R: Ion formation mechanisms in UV-MALDI. Analyst 2006, 131:966-986
Kebarle P, Verkerk UH: Electrospray: from ions in solution to ions in the gas phase, what we know now. Mass Spectrom Rev 2009, 28: 898-917
Demeure K, Quinton L, Gabelica V, De Pauw E: Rational selection of the optimum MALDI matrix for top-down proteomics by in-source decay. Anal Chem 2007, 79:8678-8685
Wiesner J, Premsler T, Sickmann A: Application of electron transfer dissociation (ETD) for the analysis of posttranslational modifications. Proteomics 2008, 8:4466-4483
Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature 2003, 422:198-207
Nesvizhskii AI, Vitek O, Aebersold R: Analysis and validation of proteomic data generated by tandem mass spectrometry. Nat Methods 2007, 4:787-797 (Pubitemid 350055575)
